Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.

2. Inject slowly down the vial wall; avoid foaming.

3. Gently swirl/roll until dissolved (do not shake).

4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

5. Use within 45-60 days of reconstitution

Protocol Overview

Concise summary of the once‑weekly regimen.

• Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.

• Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.

• Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.

• Reconstitution: 3.0 mL per 30 mg vial (10.0 mg/mL) — all doses fit in a single syringe.

• Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.

Dosing Protocol

Suggested weekly titration approach.

• Start: 2.5 mg once weekly for 4 weeks (initiation dose).

• Escalate: Increase by 2.5 mg every 4 weeks as tolerated.

• Maintenance: 5–15 mg weekly based on response and tolerability.

• Frequency: Once per week (subcutaneous), same day each week.

• Timing: Any time of day; with or without food; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.

• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.

• Shelf life: Use reconstituted solution within 28 days.

• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.

• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.

• All doses through 10 mg/week fit in a single 1 mL syringe at this concentration.

• Inject slowly; wait a few seconds before withdrawing the needle.

• Document weekly dose, date, and injection site to maintain consistency.

• Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.

How This Works

Tirzepatide is a novel dual agonist that simultaneously activates GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose‑dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP‑1 alone, contributing to superior weight reduction observed in clinical trials. Its ~5‑day half‑life enables convenient once‑weekly administration.

Potential Benefits & Side Effects

Observations from clinical trials and published literature.

• Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.

• Weight reduction: Clinical trials report substantial body‑weight loss (up to ~11 kg more than GLP‑1 RA comparators over 26 weeks at higher doses).

• Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.

• Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) — typically mild‑to‑moderate and dose‑dependent; gradual titration reduces incidence.

• Injection‑site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, calorie‑appropriate diet; reduced appetite may naturally decrease intake.

• Prioritize protein to preserve lean mass during weight loss.

• Combine resistance training and aerobic activity to support metabolic health.

• Stay hydrated, especially given potential gastrointestinal effects.

• Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

• Clean the vial stopper and skin with alcohol; allow to dry.

• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.

• Do not aspirate for subcutaneous injections; inject slowly and steadily.

• Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.

• Dispose of needles and syringes in a sharps container immediately after use.